Luke Sergott
Stock Analyst at Barclays
(2.15)
# 2,584
Out of 4,818 analysts
268
Total ratings
37.75%
Success rate
-7.19%
Average return
Main Sectors:
Stocks Rated by Luke Sergott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DHR Danaher | Maintains: Overweight | $205 → $215 | $196.52 | +9.40% | 39 | Apr 22, 2025 | |
| WAT Waters | Maintains: Equal-Weight | $400 → $350 | $341.29 | +2.55% | 18 | Apr 10, 2025 | |
| TWST Twist Bioscience | Maintains: Overweight | $58 → $45 | $40.14 | +12.11% | 17 | Apr 10, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Equal-Weight | $620 → $475 | $426.66 | +11.33% | 24 | Apr 10, 2025 | |
| SHC Sotera Health Company | Maintains: Overweight | $16 → $12 | $11.31 | +6.10% | 19 | Apr 10, 2025 | |
| RVTY Revvity | Maintains: Overweight | $140 → $110 | $95.21 | +15.53% | 9 | Apr 10, 2025 | |
| NTRA Natera | Maintains: Overweight | $200 → $160 | $154.48 | +3.57% | 2 | Apr 10, 2025 | |
| ILMN Illumina | Maintains: Underweight | $100 → $77 | $77.60 | -0.77% | 17 | Apr 10, 2025 | |
| GH Guardant Health | Maintains: Overweight | $60 → $55 | $47.33 | +16.21% | 2 | Apr 10, 2025 | |
| EXAS Exact Sciences | Maintains: Overweight | $65 → $55 | $45.59 | +20.65% | 3 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $160 → $145 | $115.89 | +25.12% | 5 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $13 → $11 | $14.43 | -23.77% | 16 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $50 | $38.88 | +28.60% | 3 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $18 | $15.44 | +16.58% | 23 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $138 → $115 | $107.02 | +7.46% | 8 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $12 | $8.31 | +44.40% | 11 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $235 → $170 | $150.68 | +12.82% | 21 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $240 → $165 | $145.92 | +13.08% | 18 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $12 → $6 | $5.86 | +2.48% | 9 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $2 | $1.14 | +75.44% | 4 | May 10, 2024 |
Danaher
Apr 22, 2025
Maintains: Overweight
Price Target: $205 → $215
Current: $196.52
Upside: +9.40%
Waters
Apr 10, 2025
Maintains: Equal-Weight
Price Target: $400 → $350
Current: $341.29
Upside: +2.55%
Twist Bioscience
Apr 10, 2025
Maintains: Overweight
Price Target: $58 → $45
Current: $40.14
Upside: +12.11%
Thermo Fisher Scientific
Apr 10, 2025
Maintains: Equal-Weight
Price Target: $620 → $475
Current: $426.66
Upside: +11.33%
Sotera Health Company
Apr 10, 2025
Maintains: Overweight
Price Target: $16 → $12
Current: $11.31
Upside: +6.10%
Revvity
Apr 10, 2025
Maintains: Overweight
Price Target: $140 → $110
Current: $95.21
Upside: +15.53%
Natera
Apr 10, 2025
Maintains: Overweight
Price Target: $200 → $160
Current: $154.48
Upside: +3.57%
Illumina
Apr 10, 2025
Maintains: Underweight
Price Target: $100 → $77
Current: $77.60
Upside: -0.77%
Guardant Health
Apr 10, 2025
Maintains: Overweight
Price Target: $60 → $55
Current: $47.33
Upside: +16.21%
Exact Sciences
Apr 10, 2025
Maintains: Overweight
Price Target: $65 → $55
Current: $45.59
Upside: +20.65%
Apr 10, 2025
Maintains: Equal-Weight
Price Target: $160 → $145
Current: $115.89
Upside: +25.12%
Apr 10, 2025
Maintains: Equal-Weight
Price Target: $13 → $11
Current: $14.43
Upside: -23.77%
Apr 10, 2025
Maintains: Overweight
Price Target: $60 → $50
Current: $38.88
Upside: +28.60%
Apr 10, 2025
Maintains: Overweight
Price Target: $23 → $18
Current: $15.44
Upside: +16.58%
Apr 10, 2025
Maintains: Equal-Weight
Price Target: $138 → $115
Current: $107.02
Upside: +7.46%
Apr 10, 2025
Maintains: Overweight
Price Target: $15 → $12
Current: $8.31
Upside: +44.40%
Apr 10, 2025
Downgrades: Equal-Weight
Price Target: $235 → $170
Current: $150.68
Upside: +12.82%
Apr 10, 2025
Downgrades: Equal-Weight
Price Target: $240 → $165
Current: $145.92
Upside: +13.08%
Apr 10, 2025
Downgrades: Underweight
Price Target: $12 → $6
Current: $5.86
Upside: +2.48%
May 10, 2024
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $1.14
Upside: +75.44%